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Background
Monitoring antiretroviral therapy through CD4T-cell
count and viral load or reverse transcriptase assessment is
used in developed countries. However, cost implication,
demand of sophisticated equipments, high level man-
power need made such technology impracticable in most
of the African laboratory settings. Developing countries
having the fewer specialized diagnostic facilities and more
affected by the disease requires reliable and cost effective
monitoring options (W.H.O., 2003). Research works car-
ried out on various viral parameters such as p24 antigen,
plasma RNA, rapid reverse transcriptase detection method
were put into trials; p24 antigen emerged as the best pos-
sible option for African laboratories use (because of its
simplicity and affordability) and correlates well with viral
load and can be used as an alternative to viral load moni-
toring (Schupbach, et al., 2003).
Materials and methods
A total of fifty-two HIV/AIDS patients receiving care at
Murtala Muhammad Specialist Hospital Kano, Nigeria
were used in carrying out this study and twenty two were
females while thirty were males. Seventeen were about to
start antiretroviral therapy at the onset of this study
(group I), while thirty five were already receiving HAART
(group II). 5 mls of blood samples were collected into
EDTA bottles from the subjects at the onset of the study
and after three months. Three months later effect of
antiretrovirals (HAART) was monitored for both groups
by determining the mean gain in CD4 T-cell count and
drop in plasma p24 antigen.
Results
CD4T-cell count range for subjects who were about to
start HAART at the beginning this study (group I) was sig-
nificantly low: 30 – 190 cells/ml of blood (p > 0.05),
while subjects already on HAART at the beginning of this
study (group II) have shown increased CD4 T-cell count,
ranging from low to normal level after three months ther-
apy with HAART: 102–1060 cells per ml of blood (p <
0.05).
Males studied in this work have CD4T-cell count of 44–
190 cells per ml of blood in group I, while those in group
II have range of 113–1060 cells per Ml of blood sample.
Females in group I have CD4T-cell count range of 30–175
cells per ml of blood sample, in group II their CD4T-cell
count increased to a range of 102–924 cells per ml of
blood. Plasma p24 antigen concentration range of 124–
307.8 pg/ml and 127.8–237 pg/ml was recorded in
females and males in group I. Treated groups (group II)
showed an appreciable serum concentration of p24 anti-
gen, in males to be 12.1–149.2 pg/ml, while in females
the range was 6.9–184.2 pg/ml
Conclusion
The problems of cost, high level manpower need associ-
ated with primer HIV testing like viral load which are the
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bottle neck to their use in developing countries like
Nigeria can be tackled through embracing an alternative
testing algorithm like P24 antigen level in the plasma of
patients receiving antiretroviral therapy. This could pro-
vide another simple method to assess antiretroviral ther-
apy, rather than looking at CD4T-cell count alone which
some of them are latently infected but still being counted
as if they are normal cells.